|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fanali C, Lucchetti D, Farina M, Corbi M,
Cufino V, Cittadini A and Sgambato A: Cancer stem cells in
colorectal cancer from pathogenesis to therapy: Controversies and
perspectives. World J Gastroenterol. 20:923–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malapelle U: USP11 role in colorectal
cancer growing and metastatisation. EBioMedicine. 48:5–6. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodríguez-Portal JA: Efficacy and safety
of Nintedanib for the rreatment of idiopathic pulmonary fibrosis:
An update. Drugs R D. 18:19–25. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richeldi L, Costabel U, Selman M, Kim DS,
Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G,
et al: Efficacy of a tyrosine kinase inhibitor in idiopathic
pulmonary fibrosis. N Engl J Med. 365:1079–1087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crestani B, Huggins JT, Kaye M, Costabel
U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser
S, et al: Long-term safety and tolerability of nintedanib in
patients with idiopathic pulmonary fibrosis: Results from the
open-label extension study, INPULSIS-ON. Lancet Respir Med.
7:60–68. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Collard HR, Richeldi L, Kim DS, Taniguchi
H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R,
Hallmann C, et al: Acute exacerbations in the INPULSIS trials of
nintedanib in idiopathic pulmonary fibrosis. Eur Respir J.
49:16013392017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue H and Tian GY: MiR-429 regulates the
metastasis and EMT of HCC cells through targeting RAB23. Arch
Biochem Biophys. 637:48–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishijima N, Seike M, Soeno C, Chiba M,
Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A:
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small
cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian X, Wei Z, Wang J, Liu P, Qin Y and
Zhong M: MicroRNA-429 inhibits the migration and invasion of colon
cancer cells by targeting PAK6/cofilin signaling. Oncol Rep.
34:707–714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Low HB and Zhang Y: Regulatory roles of
MAPK phosphatases in cancer. Immune Netw. 16:85–98. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gaggianesi M, Turdo A, Chinnici A, Lipari
E, Apuzzo T, Benfante A, Sperduti I, Di Franco S, Meraviglia S, Lo
Presti E, et al: IL4 primes the dynamics of breast cancer
progression via DUSP4 inhibition. Cancer Res. 77:3268–3279. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang X, Li M, Zhu H, Lu X, Miao J, Du S,
Xia X and Guan W: DUSP4 promotes doxorubicin resistance in gastric
cancer through epithelial-mesenchymal transition. Oncotarget.
8:94028–94039. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wollin L, Wex E, Pautsch A, Schnapp G,
Hostettler KE, Stowasser S and Kolb M: Mode of action of nintedanib
in the treatment of idiopathic pulmonary fibrosis. Eur Respir J.
45:1434–1445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kolb M, Richeldi L, Behr J, Maher TM, Tang
W, Stowasser S, Hallmann C and du BoisRM: Nintedanib in patients
with idiopathic pulmonary fibrosis and preserved lung volume.
Thorax. 72:340–346. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao YY, Feng JB, Peng J, Meng LH, Zhang
HX and Wu ML: Signal mining and post-marketing evaluation of
adverse drug reactions of nintedanib. Zhongguo Yiyuan Yaoxue Zazhi.
39:1655–1658. 2019.(In Chinese).
|
|
19
|
Januszyk P, Januszyk K, Wierzbik-Strońsk
M, Boroń D and Grabarek B: Analysis of the differences in the
expression of mRNAs and miRNAs associated with drug resistance in
endometrial cancer cells treated with salinomycin. Curr Pharm
Biotechnol. June 29–2020.https://doi.org/10.2174/1389201021666200629151008
|
|
20
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu CL, Ho JY, Hung SH and Yu DS: miR-429
expression in bladder cancer and its correlation with tumor
behavior and clinical outcome. Kaohsiung J Med Sci. 34:335–340.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang M, Dong BB, Lu M, Zheng MJ, Chen H,
Ding JZ, Xu AM and Xu YH: miR-429 functions as a tumor suppressor
by targeting FSCN1 in gastric cancer cells. Onco Targets Ther.
9:1123–1133. 2016.PubMed/NCBI
|
|
25
|
Guo C, Zhao D, Zhang Q, Liu S and Sun MZ:
miR-429 suppresses tumor migration and invasion by targeting CRKL
in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and
epithelial-mesenchymal transition. Sci Rep. 8:23752018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu
Z, Liu T and Hu F: Downregulation of miR-429 and inhibition of cell
migration and invasion in nasopharyngeal carcinoma. Mol Med Rep.
13:3236–3242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han Y, Zhao Q, Zhou J and Shi R: miR-429
mediates tumor growth and metastasis in colorectal cancer. Am J
Cancer Res. 7:218–233. 2017.PubMed/NCBI
|
|
28
|
Xiao P, Liu W and Zhou H: miR-429 promotes
the proliferation of non-small cell lung cancer cells via targeting
DLC-1. Oncol Lett. 12:2163–2168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Z, Zhu Z, Lin Z, Luo Y, Liang Z,
Zhang C, Chen J and Peng P: miR-429 suppresses cell proliferation,
migration and invasion in nasopharyngeal carcinoma by
downregulation of TLN1. Cancer Cell Int. 19:1152019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ha J, Kang E, Seo J and Cho S:
Phosphorylation dynamics of JNK signaling: Effects of
dual-specificity phosphatases (DUSPs) on the JNK pathway. Int J Mol
Sci. 20:61572019.doi: 10.3390/ijms20246157. View Article : Google Scholar
|
|
31
|
Chen P, Hutter D, Yang X, Gorospe M, Davis
RJ and Liu Y: Discordance between the binding affinity of
mitogen-activated protein kinase subfamily members for MAP kinase
phosphatase-2 and their ability to activate the phosphatase
catalytically. J Biol Chem. 276:29440–29449. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Muhammad T, Zhang J, Ma Y, Li Y, Zhang F,
Zhang Y and Liang Y: Overexpression of a mitogen-activated protein
kinase SlMAPK3 positively regulates tomato tolerance to cadmium and
drought stress. Molecules. 24:5562019.https://doi.org/10.3390/molecules24030556 View Article : Google Scholar
|
|
33
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raitano AB, Halpern JR, Hambuch TM and
Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and
requires Jun for transformation. Proc Natl Acad Sci USA.
92:11746–11750. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Siddiqui MA and Reddy PA: Small molecule
JNK (c-Jun N-terminal kinase) inhibitors. J Med Chem. 53:3005–3012.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Davis RJ: Signal transduction by the JNK
group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
|
